Eurofins Strengthens Its Genomics and Genetic Testing Footprint with the Acquisition of GATC in Germany
02 June 2017 - 4:00PM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), a global leader in
bio-analytical testing, announces that it has signed an agreement
to acquire GATC Biotech AG (“GATC”), one of Europe’s specialists in
DNA sequencing. The transaction is expected to close in July,
subject to the fulfilment of customary closing conditions.
Founded in 1990, GATC has achieved a strong recognition for DNA
and RNA sequencing, as well as bioinformatics in Europe. The
company employs 140 staff across 2 sites, and serves over 10,000
institutional and academic customers, generating annual revenues of
about EUR 20m. As one of the larger players in Custom and Next
Generation Sequencing, GATC has built a reputation for innovative,
internally-developed applications, as well as industry-leading
turn-around time (TAT). The acquisition should therefore further
reinforce Eurofins' footprint in DNA sequencing, and strengthen the
Group's technological platform supporting its genetic testing
innovations.
Comment from Peter Pohl, CEO and Co-founder of GATC: “We are
excited to be joining the Eurofins family of laboratories and look
forward to the next phase of our development within the Group. We
are confident that with access to Eurofins’ global network and
technical competencies, we should be able to expand our analytical
portfolio and services to benefit all our existing and future
clients.”
Comment from Dr. Gilles Martin, Eurofins CEO: “We look forward
to providing GATC access to the complete capabilities of the
Eurofins Group. This transaction is a demonstration of Eurofins'
commitment to genomics services. We believe that advances in gene
sequencing will continue to drive innovations not only in clinical
diagnostics, but in the broader bioanalytical testing market as
well."
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 28,000
staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170601006111/en/
Investor RelationsEurofins ScientificPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024